Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | GYS1 | P13807 | 2/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30369520 | 1.00 | MAPT (0.34) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL23926386 | 0.86 | GHSR (0.37) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL30369527 | 0.86 | GHSR (0.37) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL30369775 | 0.83 | PREP (0.37) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL23926358 | 0.83 | PREP (0.37) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL23926345 | 0.81 | PREP (0.41) | L3MBTL1HCRTR1HCRTR2PREPAPP | |
| SCHEMBL23926371 | 0.77 | APP (0.40) | PREPPTGER1APP | |
| SCHEMBL30118918 | 0.76 | KLK7 (0.47) | MAPTL3MBTL1PREP | |
| SCHEMBL23964440 | 0.76 | KLK7 (0.47) | MAPTL3MBTL1PREP | |
| SCHEMBL23964599 | 0.73 | KLK7 (0.44) | PREPAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | MAPT 6/4885CYP2C9 4492/4885CYP2C19 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.